AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation

CompletedOBSERVATIONAL
Enrollment

52

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

April 7, 2024

Study Completion Date

April 7, 2024

Conditions
Kidney Transplant Failure and Rejection
Interventions
DIAGNOSTIC_TEST

AlloSure ddcfDNA assay

2.5 mL collection for Donor Derived Cell Free DNA at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C

DIAGNOSTIC_TEST

AlloMap assay

10 mL collection PAXgene blood sample at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C

DIAGNOSTIC_TEST

Inflammatory Cytokines

10 mL collection at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A

DIAGNOSTIC_TEST

Immune Cell Phenotypes

Collection of up to 1 cup of urine for per participant each study visit

Trial Locations (1)

53705

University of Wisconsin - Madison, Madison

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

CareDx

INDUSTRY

lead

University of Wisconsin, Madison

OTHER

NCT04057742 - AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation | Biotech Hunter | Biotech Hunter